Report
EUR 13.66 For Business Accounts Only

PENUMBRA increases its risk exposure and slightly lowers to Neutral

PENUMBRA (US), a company active in the Medical Equipment industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date November 9, 2021, the closing price was USD 274.78 and its expected value was estimated at USD 271.97.
Underlying
Penumbra Inc.

Penumbra is a healthcare company. The company designs, develops, manufactures and markets medical devices. The company's Neuro products include Penumbra System brand of products that provides a form of mechanical thrombectomy used by specialist physicians to revascularize blood vessels that are blocked by clots in the intracranial vasculature. The company's Vascular products include the Ruby Coil System that consists of detachable coils and is used in clinical applications auch as active extravasations, or the escape of blood into surrounding tissue, selective embolization in patients with visceral aneurysms, embolization in patients with gastrointestinal bleeding, and high flow arterial venous malformations.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch